These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31098984)

  • 1. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
    Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
    Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.
    Sowa-Staszczak A; Pach D; Mikołajczak R; Mäcke H; Jabrocka-Hybel A; Stefańska A; Tomaszuk M; Janota B; Gilis-Januszewska A; Małecki M; Kamiński G; Kowalska A; Kulig J; Matyja A; Osuch C; Hubalewska-Dydejczyk A
    Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):524-31. PubMed ID: 23224740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
    Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
    J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
    Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
    J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
    Wild D; Antwi K; Fani M; Christ ER
    J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
    Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
    Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
    Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
    J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A freeze-dried kit formulation for the preparation of Lys(27)(99mTc-EDDA/HYNIC)-Exendin(9-39)/99mTc-EDDA/HYNIC-Tyr3-Octreotide to detect benign and malignant insulinomas.
    Medina-García V; Ocampo-García BE; Ferro-Flores G; Santos-Cuevas CL; Aranda-Lara L; García-Becerra R; Ordaz-Rosado D; Melendez-Alafort L
    Nucl Med Biol; 2015 Dec; 42(12):911-6. PubMed ID: 26364504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
    Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Otani D; Murakami T; Murakami S; Hanaoka I; Fujimoto H; Shimizu Y; Kawai Miyake K; Sakaki K; Ueda Y; Tanaka D; Ohno T; Shimizu H; Uyama N; Iizuka N; Yabe D; Nakamoto Y; Inagaki N
    Endocr J; 2024 Sep; 71(9):925-933. PubMed ID: 38839345
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Sakaki K; Murakami T; Fujimoto H; Shimizu Y; Miyake KK; Otani D; Kiyobayashi S; Okada T; Fujimoto M; Hakata T; Yamauchi I; Shimada K; Shimizu H; Nagai K; Nakamoto Y; Inagaki N
    Front Endocrinol (Lausanne); 2023; 14():1245573. PubMed ID: 37720533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
    Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
    Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
    Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
    Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
    Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of
    Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
    Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
    Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.
    Sowa-Staszczak A; Trofimiuk-Müldner M; Stefańska A; Tomaszuk M; Buziak-Bereza M; Gilis-Januszewska A; Jabrocka-Hybel A; Głowa B; Małecki M; Bednarczuk T; Kamiński G; Kowalska A; Mikołajczak R; Janota B; Hubalewska-Dydejczyk A
    PLoS One; 2016; 11(8):e0160714. PubMed ID: 27526057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
    Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
    Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
    [No Abstract]   [Full Text] [Related]  

  • 20. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
    Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
    J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.